Loading
Latest filing published 11 Jan 2023 for Jounce Therapeutics, Inc., €7,692. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Hugh M. Cole, listed as senior executive, appears in our data through filings on Jounce Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 7 January 2022 to 9 January 2023, the count stands at 4 filings.
On the market, this insider has only sold: 2 sales, €30k in total. Other entries cover 2 share grants. In 2023 alone, the filings show no purchases and 1 sale.
On 11 January 2023 came the latest disclosure, an open-market sale for €7,692 in Jounce Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations